Deciphering spreading mechanisms in amyotrophic lateral sclerosis: Clinical evidence and potential molecular processes

Current Opinion in Neurology

Volumn 28, Issue 5, 2015, Pages 455-461

  Pradat, Pierre François ^a,b   Kabashi, Edor ^b,c   Desnuelle, Claude ^d,e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^d PASTEUR HOSPITAL   (France)

^e UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

Author keywords

Amyotrophic lateral Sclerosis; Fused In Sarcoma; Neuroimaging; Prion Like Mechanism; Spreading; Superoxide Dismutase 1; Tdp 43

Indexed keywords

PRION PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; AUTOPSY; BODY REGIONS; DEGENERATIVE DISEASE; ELECTROPHYSIOLOGY; HUMAN; LONGITUDINAL STUDY; NERVE CELL; NERVE CELL LESION; NEUROIMAGING; PROTEIN FOLDING; PROTEIN SECRETION; REVIEW; SPINAL CORD; ANIMAL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HUMANS;

EID: 84941777004     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000239     Document Type: Review

References (48)

1. Lee S, Kim HJ. Prion-like mechanism in amyotrophic lateral sclerosis: are protein aggregates the key? Exp Neurobiol 2015; 24:1-7.
2. Maniecka Z, Polymenidou M. From nucleation to widespread propagation: a prion-like concept in ALS. Virus Res 2015. [Epub ahead of print]
3. Grad LI, Fernando SM, Cashman NR. From molecule to molecule and cell to cell: prion-like mechanisms in amyotrophic lateral sclerosis. Neurobiol Dis 2015; 77:257-265.
4. Ravits J. Focality, stochasticity and neuroanatomic propagation in ALS pathogenesis. Exp Neurol 2014; 262:121-126.
5. Devine MS, Kiernan MC, Heggie S, et al. Study of motor asymmetry in ALS indicates an effect of limb dominance on onset and spread of weakness, and an important role for upper motor neurons. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15:481-487.
6. Devine MS, Pannek K, Coulthard A, et al. Exposing asymmetric gray matter vulnerability in amyotrophic lateral sclerosis. Neuroimage Clin 2015; 7:782-787.
7. Pupillo E, Messina P, Giussani G, et al. Physical activity and amyotrophic lateral sclerosis: a European population-based case-control study. Ann Neurol 2014; 75:708-716.
8. Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013; 74:20-38.
9. Brettschneider J, Arai K, Del Tredici K, et al. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol 2014; 128:423-437.
10. Braak H, Brettschneider J, Ludolph AC, et al. Amyotrophic lateral sclerosis: a model of corticofugal axonal spread. Nat Rev Neurol 2013; 9:708-714.
11. Sekiguchi T, Kanouchi T, Shibuya K, et al. Spreading of amyotrophic lateral sclerosis lesions: multifocal hits and local propagation? J Neurol Neurosurg Psychiatry 2014; 85:85-91.
12. Chiò A, Pagani M, Agosta F, et al. Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. Lancet Neurol 2014; 13:1228-1240.
13. Pradat PF, El Mendili MM. Neuroimaging to investigate multisystem involvement and provide biomarkers in amyotrophic lateral sclerosis. Biomed Res Int 2014; 2014: Article ID 467560.
14. Bede P, Elamin M, Byrne S, et al. Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology 2013; 8:12107-12115.
15. Pagani M, Chiò A, Valentini MC, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology 2014; 83:1067-1074.
16. Bede P, Elamin M, Byrne S, et al. Patterns of cerebral and cerebellar white matter degeneration in ALS. J Neurol Neurosurg Psychiatry 2015; 86:468-470.
17. Lattante S, Ciura S, Rouleau GA, Kabashi E. Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD). Trends Genet 2015; 5:263-273.
18. Rajagopalan V, Pioro EP. Distinct patterns of cortical atrophy in ALS patients with or without dementia: an MRI VBM study. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15:216-225.
19. Kasper E, Schuster C, Machts J, et al. Microstructural white matter changes underlying cognitive and behavioural impairment in ALS: an in vivo study using DTI. PLoS One 2014; 9:e114543.
20. Kassubek J, Müller HP, Del Tredici K, et al. Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain 2014; 137:1733-1740.
21. Schmidt R, de Reus MA, Scholtens LH, et al. Simulating disease propagation across white matter connectome reveals anatomical substrate for neuropathology staging in amyotrophic lateral sclerosis. Neuroimage 2015. [Epub ahead of print]
22. Menke RA, Körner S, Filippini N, et al. Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain 2014; 137:2546-2555.
23. El Mendili MM, Cohen-Adad J, Pelegrini-Issac M, et al. Multiparametric spinal cord MRI as potential progression marker in amyotrophic lateral sclerosis. PLoS One 2014; 9:e95516.
24. Iglesias C, Sangari S, El Mendili MM, et al. Electrophysiological and spinal imaging evidences for sensory dysfunction in amyotrophic lateral sclerosis. Br Med J Open 2015; 5:e007659.
25. El Mendili MM, Chen R, Tiret B, et al. Fast and accurate semi-automated segmentation method of spinal cord MR images at 3T applied to the construction of a cervical spinal cord template. PLoS One 2015; 10:e0122224.
26. Fonov VS, Le Troter A, Taso M, et al. Framework for integrated MRI average of the spinal cord white and gray matter: the MNI-Poly-AMU template. Neuroimage 2014; 102:817-827.
27. Kong Y, Eippert F, Beckmann CF, et al. Intrinsically organized resting state networks in the human spinal cord. Proc Natl Acad Sci U S A 2014; 111:18067-18072.
28. Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014; 17:17-23.
29. Palomo GM, Manfredi G. Exploring new pathways of neurodegeneration in ALS: the role of mitochondria quality control. Brain Res 2015; 1607:36-46.
30. Poppe L, RuéL, Robberecht W, Van Den Bosch L. Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS). Exp Neurol 2014; 262:138-151.
31. Lattante S, Rouleau GA, Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum Mutat 2013; 34:812-826.
32. Budini M, Baralle FE, Buratti E. Targeting TDP-43 in neurodegenerative diseases. Expert Opin Ther Targets 2014; 18:617-632.
33. Clement AM, Nguyen MD, Roberts EA, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003; 302:113-117.
34. Rakhit R, Robertson J, Vande Velde C, et al. An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat Med 2007; 13:754-759.
35. Basso M1, Pozzi S, Tortarolo M, et al. Mutant copper-zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis. J Biol Chem 2013; 288:15699-15711.
36. Kabashi E, Bercier V, Lissouba A, et al. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoSGenet 2011; 7:e1002214.
37. Arai T. Significance and limitation of the pathological classification of TDP-43 proteinopathy. Neuropathology 2014; 34:578-588.
38. Zhang YJ, Xu YF, Dickey CA, et al. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci 2007; 27:10530-10534.
39. Xiao S, Sanelli T, Chiang H, et al. Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death. Acta Neuropathol 2015; 130:49-61.
40. Cohen TJ, Hwang AW, Restrepo CR, et al. An acetylation switch controls TDP-43 function and aggregation propensity. Nat Commun 2015; 6:5845.
41. Alami NH, Smith RB, Carrasco MA, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 2014; 81:536-543.
42. Nomura T1, Watanabe S, Kaneko K, et al. Intranuclear aggregation of mutant FUS/TLS as a molecular pathomechanism of amyotrophic lateral sclerosis. J Biol Chem 2014; 289:1192-1202.
43. Haeusler AR, Donnelly CJ, Periz G, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 2014; 507:524-528.
44. Kwon I1, Xiang S1, Kato M1, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 2014; 345:1139-1145.
45. May S, Hornburg D, Schludi MH, et al. C9orf72 FTLD/ALS-associated Gly- Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol 2014; 128:485-503.
46. Müch C, O'Brien J, Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci USA 2011; 108:3548-3553.
47. Re DB, Le verche V, Yu C, et al. Neuroptosis drive motor neuron death in models of both sporadic and familial ALS. Neuron 2014; 81:1001-1008.
48. Kang SH, Li Y, Fukaya M, et al. Degeneration and impaired regeneration of grey matter oligodendrocytes in Amyotrophic lateral Sclerosis. Nat Neurosci 2013; 16:571-579.